Skip to main content

Blood Pressure clinical trials at UCSF

3 in progress, 1 open to eligible people

Blood pressure is a measure of the force of blood against the walls of your arteries. UCSF is recruiting for a clinical trial called "Sleep and Social Experiences Study 2." This trial will study the effects of sleep loss on discrimination and heart health. There are two more related trials in progress, but not open to new participants.

Showing trials for
  • Sleep and Social Experiences Study 2

    open to eligible people ages 18-64

    This study aims to to test effects of sleep loss on perceived discrimination and cardiovascular functioning as well as identify moderators of the racial discrimination and objective sleep link in a sample of 80 African Americans.

    San Francisco, California

  • Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD

    Sorry, currently not accepting new patients, but might later

    The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a vulnerable and challenging period of time for patients and providers. Suboptimal control of blood pressure is known to be common in patients with the advanced stages of CKD, and may contribute to their elevated risk of progression to ESRD, cardiovascular morbidity, and mortality. This proposal is a pilot randomized controlled trial designed to test whether intensive blood pressure lowering is feasible and safe in patients with advanced CKD as they transition to ESRD.

    San Francisco, California

  • ACEi ARB Withdrawal in CKD Patients

    Sorry, not yet accepting patients

    The American Heart Association guidelines for high blood pressure (BP) currently recommend using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) as first-line therapy for patients with chronic kidney disease (CKD) stage 3 or above. However, the prevalence of ACEi and ARB use in patients with CKD stage 4 or 5 is low, and current BP guidelines acknowledge the lack of solid evidence to support the benefit of using these agents in advanced CKD.This study seeks to conduct a pilot trial to determine the safety and feasibility of ACEi and/or ARB continuation (intervention) versus withdrawal (control) in patients with advanced CKD.

    San Francisco, California

Our lead scientists for Blood Pressure research studies include .

Last updated: